{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:50:31Z","timestamp":1787503831041,"version":"build-2736575974"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,3,2]],"date-time":"2020-03-02T00:00:00Z","timestamp":1583107200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,3,2]],"date-time":"2020-03-02T00:00:00Z","timestamp":1583107200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s40257-020-00509-z","type":"journal-article","created":{"date-parts":[[2020,3,2]],"date-time":"2020-03-02T08:03:08Z","timestamp":1583136188000},"page":"493-504","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Long-Term Outcomes in BRAF-Mutated Melanoma Treated with Combined Targeted Therapy or Immune Checkpoint Blockade: Are We Approaching a True Cure?"],"prefix":"10.1007","volume":"21","author":[{"given":"Patrick","family":"Schummer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8859-4103","authenticated-orcid":false,"given":"Bastian","family":"Schilling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Gesierich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,2]]},"reference":[{"issue":"1","key":"509_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7\u201334. https:\/\/doi.org\/10.3322\/caac.21551.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"509_CR2","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.cell.2012.06.024","volume":"150","author":"E Hodis","year":"2012","unstructured":"Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, et al. A landscape of driver mutations in melanoma. Cell. 2012;150(2):251\u201363. https:\/\/doi.org\/10.1016\/j.cell.2012.06.024.","journal-title":"Cell"},{"issue":"6892","key":"509_CR3","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/nature00766","volume":"417","author":"H Davies","year":"2002","unstructured":"Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949\u201354. https:\/\/doi.org\/10.1038\/nature00766.","journal-title":"Nature"},{"issue":"7","key":"509_CR4","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1056\/NEJMoa1904059","volume":"381","author":"C Robert","year":"2019","unstructured":"Robert C, Grob JJ, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E, et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med. 2019;381(7):626\u201336. https:\/\/doi.org\/10.1056\/NEJMoa1904059.","journal-title":"N Engl J Med"},{"key":"509_CR5","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ejca.2016.12.010","volume":"73","author":"T Amaral","year":"2017","unstructured":"Amaral T, Sinnberg T, Meier F, Krepler C, Levesque M, Niessner H, et al. The mitogen-activated protein kinase pathway in melanoma part I\u2014activation and primary resistance mechanisms to BRAF inhibition. Eur J Cancer. 2017;73:85\u201392. https:\/\/doi.org\/10.1016\/j.ejca.2016.12.010.","journal-title":"Eur J Cancer"},{"key":"509_CR6","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ejca.2016.12.012","volume":"73","author":"T Amaral","year":"2017","unstructured":"Amaral T, Sinnberg T, Meier F, Krepler C, Levesque M, Niessner H, et al. MAPK pathway in melanoma part II\u2014secondary and adaptive resistance mechanisms to BRAF inhibition. Eur J Cancer. 2017;73:93\u2013101. https:\/\/doi.org\/10.1016\/j.ejca.2016.12.012.","journal-title":"Eur J Cancer"},{"issue":"12","key":"509_CR7","doi-asserted-by":"publisher","first-page":"5414","DOI":"10.1002\/cam4.2248","volume":"8","author":"Q Yu","year":"2019","unstructured":"Yu Q, Xie J, Li J, Lu Y, Liao L. Clinical outcomes of BRAF plus MEK inhibition in melanoma: a meta-analysis and systematic review. Cancer Med. 2019;8(12):5414\u201324. https:\/\/doi.org\/10.1002\/cam4.2248.","journal-title":"Cancer Med"},{"issue":"1","key":"509_CR8","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1158\/2159-8290.CD-13-0642","volume":"4","author":"H Shi","year":"2014","unstructured":"Shi H, Hugo W, Kong X, Hong A, Koya RC, Moriceau G, et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov. 2014;4(1):80\u201393. https:\/\/doi.org\/10.1158\/2159-8290.CD-13-0642.","journal-title":"Cancer Discov"},{"issue":"20","key":"509_CR9","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","volume":"371","author":"GV Long","year":"2014","unstructured":"Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014;371(20):1877\u201388. https:\/\/doi.org\/10.1056\/NEJMoa1406037.","journal-title":"N Engl J Med"},{"issue":"1","key":"509_CR10","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1056\/NEJMoa1412690","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372(1):30\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1412690.","journal-title":"N Engl J Med"},{"issue":"20","key":"509_CR11","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","volume":"371","author":"J Larkin","year":"2014","unstructured":"Larkin J, Ascierto PA, Dreno B, Atkinson V, Liszkay G, Maio M, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014;371(20):1867\u201376. https:\/\/doi.org\/10.1056\/NEJMoa1408868.","journal-title":"N Engl J Med"},{"issue":"5","key":"509_CR12","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/S1470-2045(18)30142-6","volume":"19","author":"R Dummer","year":"2018","unstructured":"Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2018;19(5):603\u201315. https:\/\/doi.org\/10.1016\/S1470-2045(18)30142-6.","journal-title":"Lancet Oncol"},{"issue":"9","key":"509_CR13","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","volume":"17","author":"PA Ascierto","year":"2016","unstructured":"Ascierto PA, McArthur GA, Dreno B, Atkinson V, Liszkay G, Di Giacomo AM, et al. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 2016;17(9):1248\u201360. https:\/\/doi.org\/10.1016\/S1470-2045(16)30122-X.","journal-title":"Lancet Oncol"},{"issue":"10","key":"509_CR14","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1001\/jamaoncol.2018.2668","volume":"4","author":"A Hauschild","year":"2018","unstructured":"Hauschild A, Larkin J, Ribas A, Dreno B, Flaherty KT, Ascierto PA, et al. Modeled prognostic subgroups for survival and treatment outcomes in BRAF V600-mutated metastatic melanoma: pooled analysis of 4 randomized clinical trials. JAMA Oncol. 2018;4(10):1382\u20138. https:\/\/doi.org\/10.1001\/jamaoncol.2018.2668.","journal-title":"JAMA Oncol"},{"issue":"10","key":"509_CR15","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/S1470-2045(18)30497-2","volume":"19","author":"R Dummer","year":"2018","unstructured":"Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, et al. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018;19(10):1315\u201327. https:\/\/doi.org\/10.1016\/S1470-2045(18)30497-2.","journal-title":"Lancet Oncol"},{"issue":"4","key":"509_CR16","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1093\/annonc\/mdz011","volume":"30","author":"O Hamid","year":"2019","unstructured":"Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol. 2019;30(4):582\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdz011.","journal-title":"Ann Oncol"},{"issue":"9","key":"509_CR17","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","volume":"20","author":"C Robert","year":"2019","unstructured":"Robert C, Ribas A, Schachter J, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 2019;20(9):1239\u201351. https:\/\/doi.org\/10.1016\/S1470-2045(19)30388-2.","journal-title":"Lancet Oncol"},{"key":"509_CR18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910836","author":"J Larkin","year":"2019","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019. https:\/\/doi.org\/10.1056\/NEJMoa1910836.","journal-title":"N Engl J Med"},{"issue":"4","key":"509_CR19","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1200\/JCO.2016.71.8023","volume":"36","author":"J Larkin","year":"2018","unstructured":"Larkin J, Minor D, D'Angelo S, Neyns B, Smylie M, Miller WH Jr, et al. Overall survival in patients with advanced melanoma who received nivolumab versus investigator's choice chemotherapy in CheckMate 037: a randomized, controlled, open-label phase III trial. J Clin Oncol. 2018;36(4):383\u201390. https:\/\/doi.org\/10.1200\/JCO.2016.71.8023.","journal-title":"J Clin Oncol"},{"issue":"1","key":"509_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.soc.2010.09.007","volume":"20","author":"PV Dickson","year":"2011","unstructured":"Dickson PV, Gershenwald JE. Staging and prognosis of cutaneous melanoma. Surg Oncol Clin N Am. 2011;20(1):1\u201317. https:\/\/doi.org\/10.1016\/j.soc.2010.09.007.","journal-title":"Surg Oncol Clin N Am"},{"issue":"6","key":"509_CR21","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3322\/caac.21409","volume":"67","author":"JE Gershenwald","year":"2017","unstructured":"Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(6):472\u201392. https:\/\/doi.org\/10.3322\/caac.21409.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"509_CR22","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1200\/JCO.2011.38.0527","volume":"30","author":"PW Sperduto","year":"2012","unstructured":"Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X, et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol. 2012;30(4):419\u201325. https:\/\/doi.org\/10.1200\/JCO.2011.38.0527.","journal-title":"J Clin Oncol"},{"issue":"7","key":"509_CR23","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/S1470-2045(17)30429-1","volume":"18","author":"MA Davies","year":"2017","unstructured":"Davies MA, Saiag P, Robert C, Grob JJ, Flaherty KT, Arance A, et al. Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol. 2017;18(7):863\u201373. https:\/\/doi.org\/10.1016\/S1470-2045(17)30429-1.","journal-title":"Lancet Oncol"},{"issue":"5","key":"509_CR24","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/S1470-2045(18)30139-6","volume":"19","author":"GV Long","year":"2018","unstructured":"Long GV, Atkinson V, Lo S, Sandhu S, Guminski AD, Brown MP, et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol. 2018;19(5):672\u201381. https:\/\/doi.org\/10.1016\/S1470-2045(18)30139-6.","journal-title":"Lancet Oncol"},{"issue":"8","key":"509_CR25","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa1805453","volume":"379","author":"HA Tawbi","year":"2018","unstructured":"Tawbi HA, Forsyth PA, Algazi A, Hamid O, Hodi FS, Moschos SJ, et al. Combined nivolumab and ipilimumab in melanoma metastatic to the brain. N Engl J Med. 2018;379(8):722\u201330. https:\/\/doi.org\/10.1056\/NEJMoa1805453.","journal-title":"N Engl J Med"},{"issue":"7","key":"509_CR26","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/s41416-019-0546-y","volume":"121","author":"KD Lewis","year":"2019","unstructured":"Lewis KD, Larkin J, Ribas A, Flaherty KT, McArthur GA, Ascierto PA, et al. Impact of depth of response on survival in patients treated with cobimetinib +\/\u2212 vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM. Br J Cancer. 2019;121(7):522\u20138. https:\/\/doi.org\/10.1038\/s41416-019-0546-y.","journal-title":"Br J Cancer"},{"issue":"33","key":"509_CR27","doi-asserted-by":"publisher","first-page":"3142","DOI":"10.1200\/JCO.19.00489","volume":"37","author":"C Menzer","year":"2019","unstructured":"Menzer C, Menzies AM, Carlino MS, Reijers I, Groen EJ, Eigentler T, et al. Targeted therapy in advanced melanoma with rare BRAF mutations. J Clin Oncol. 2019;37(33):3142\u201351. https:\/\/doi.org\/10.1200\/JCO.19.00489.","journal-title":"J Clin Oncol"},{"issue":"1","key":"509_CR28","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1158\/1535-7163.MCT-13-0212","volume":"13","author":"J Wang","year":"2014","unstructured":"Wang J, Chen J, Miller DD, Li W. Synergistic combination of novel tubulin inhibitor ABI-274 and vemurafenib overcome vemurafenib acquired resistance in BRAFV600E melanoma. Mol Cancer Ther. 2014;13(1):16\u201326. https:\/\/doi.org\/10.1158\/1535-7163.MCT-13-0212.","journal-title":"Mol Cancer Ther"},{"issue":"7658","key":"509_CR29","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/nature22794","volume":"546","author":"SM Shaffer","year":"2017","unstructured":"Shaffer SM, Dunagin MC, Torborg SR, Torre EA, Emert B, Krepler C, et al. Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance. Nature. 2017;546(7658):431\u20135. https:\/\/doi.org\/10.1038\/nature22794.","journal-title":"Nature"},{"issue":"7326","key":"509_CR30","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/nature09626","volume":"468","author":"R Nazarian","year":"2010","unstructured":"Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010;468(7326):973\u20137. https:\/\/doi.org\/10.1038\/nature09626.","journal-title":"Nature"},{"issue":"33","key":"509_CR31","doi-asserted-by":"publisher","first-page":"28087","DOI":"10.1074\/jbc.M112.377218","volume":"287","author":"V Yadav","year":"2012","unstructured":"Yadav V, Zhang X, Liu J, Estrem S, Li S, Gong XQ, et al. Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)\/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma. J Biol Chem. 2012;287(33):28087\u2013988. https:\/\/doi.org\/10.1074\/jbc.M112.377218.","journal-title":"J Biol Chem"},{"issue":"7377","key":"509_CR32","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/nature10662","volume":"480","author":"PI Poulikakos","year":"2011","unstructured":"Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature. 2011;480(7377):387\u201390. https:\/\/doi.org\/10.1038\/nature10662.","journal-title":"Nature"},{"issue":"2","key":"509_CR33","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/pcmr.12197","volume":"27","author":"J Choi","year":"2014","unstructured":"Choi J, Landrette SF, Wang T, Evans P, Bacchiocchi A, Bjornson R, et al. Identification of PLX4032-resistance mechanisms and implications for novel RAF inhibitors. Pigment Cell Melanoma Res. 2014;27(2):253\u201362. https:\/\/doi.org\/10.1111\/pcmr.12197.","journal-title":"Pigment Cell Melanoma Res"},{"issue":"12","key":"509_CR34","doi-asserted-by":"publisher","first-page":"e28973","DOI":"10.1371\/journal.pone.0028973","volume":"6","author":"M Atefi","year":"2011","unstructured":"Atefi M, von Euw E, Attar N, Ng C, Chu C, Guo D, et al. Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT\/mTOR pathway. PLoS One. 2011;6(12):e28973. https:\/\/doi.org\/10.1371\/journal.pone.0028973.","journal-title":"PLoS One"},{"issue":"7","key":"509_CR35","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1158\/0008-5472.CAN-10-2954","volume":"71","author":"KH Paraiso","year":"2011","unstructured":"Paraiso KH, Xiang Y, Rebecca VW, Abel EV, Chen YA, Munko AC, et al. PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res. 2011;71(7):2750\u201360. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-2954.","journal-title":"Cancer Res"},{"issue":"6","key":"509_CR36","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.cell.2015.07.061","volume":"162","author":"W Hugo","year":"2015","unstructured":"Hugo W, Shi H, Sun L, Piva M, Song C, Kong X, et al. Non-genomic and immune evolution of melanoma acquiring MAPKi resistance. Cell. 2015;162(6):1271\u201385. https:\/\/doi.org\/10.1016\/j.cell.2015.07.061.","journal-title":"Cell"},{"issue":"1","key":"509_CR37","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","volume":"165","author":"W Hugo","year":"2016","unstructured":"Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell. 2016;165(1):35\u201344. https:\/\/doi.org\/10.1016\/j.cell.2016.02.065.","journal-title":"Cell"},{"key":"509_CR38","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.ejca.2019.05.015","volume":"116","author":"S Kreft","year":"2019","unstructured":"Kreft S, Gesierich A, Eigentler T, Franklin C, Valpione S, Ugurel S, et al. Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma. Eur J Cancer. 2019;116:207\u201315. https:\/\/doi.org\/10.1016\/j.ejca.2019.05.015.","journal-title":"Eur J Cancer"},{"issue":"2","key":"509_CR39","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1111\/pcmr.12831","volume":"33","author":"R Mason","year":"2020","unstructured":"Mason R, Dearden HC, Nguyen B, Oon JS, Smith JL, Randhawa M, et al. Combined ipilimumab and nivolumab first-line and after BRAF targeted therapy in advanced melanoma. Pigment Cell Melanoma Res. 2020;33(2):358\u201365. https:\/\/doi.org\/10.1111\/pcmr.12831.","journal-title":"Pigment Cell Melanoma Res"},{"issue":"11","key":"509_CR40","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1002\/cncr.28620","volume":"120","author":"A Ackerman","year":"2014","unstructured":"Ackerman A, Klein O, McDermott DF, Wang W, Ibrahim N, Lawrence DP, et al. Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. Cancer. 2014;120(11):1695\u2013701. https:\/\/doi.org\/10.1002\/cncr.28620.","journal-title":"Cancer"},{"issue":"6","key":"509_CR41","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s11523-019-00688-8","volume":"14","author":"AM Czarnecka","year":"2019","unstructured":"Czarnecka AM, Teterycz P, Mariuk-Jarema A, Lugowska I, Rogala P, Dudzisz-Sledz M, et al. Treatment sequencing and clinical outcomes in BRAF-positive and BRAF-negative unresectable and metastatic melanoma patients treated with new systemic therapies in routine practice. Target Oncol. 2019;14(6):729\u201342. https:\/\/doi.org\/10.1007\/s11523-019-00688-8.","journal-title":"Target Oncol"},{"issue":"2","key":"509_CR42","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1158\/2159-8290.CD-16-1223","volume":"7","author":"DS Shin","year":"2017","unstructured":"Shin DS, Zaretsky JM, Escuin-Ordinas H, Garcia-Diaz A, Hu-Lieskovan S, Kalbasi A, et al. Primary resistance to PD-1 blockade mediated by JAK1\/2 mutations. Cancer Discov. 2017;7(2):188\u2013201. https:\/\/doi.org\/10.1158\/2159-8290.CD-16-1223.","journal-title":"Cancer Discov"},{"key":"509_CR43","doi-asserted-by":"publisher","first-page":"15440","DOI":"10.1038\/ncomms15440","volume":"8","author":"A Sucker","year":"2017","unstructured":"Sucker A, Zhao F, Pieper N, Heeke C, Maltaner R, Stadtler N, et al. Acquired IFNgamma resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions. Nat Commun. 2017;8:15440. https:\/\/doi.org\/10.1038\/ncomms15440.","journal-title":"Nat Commun"},{"issue":"1","key":"509_CR44","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1038\/s41467-017-01062-w","volume":"8","author":"M Sade-Feldman","year":"2017","unstructured":"Sade-Feldman M, Jiao YJ, Chen JH, Rooney MS, Barzily-Rokni M, Eliane JP, et al. Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nat Commun. 2017;8(1):1136. https:\/\/doi.org\/10.1038\/s41467-017-01062-w.","journal-title":"Nat Commun"},{"issue":"12","key":"509_CR45","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1038\/s41591-019-0654-5","volume":"25","author":"D Liu","year":"2019","unstructured":"Liu D, Schilling B, Liu D, Sucker A, Livingstone E, Jerby-Amon L, et al. Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. Nat Med. 2019;25(12):1916\u201327. https:\/\/doi.org\/10.1038\/s41591-019-0654-5.","journal-title":"Nat Med"},{"key":"509_CR46","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ejca.2017.01.009","volume":"75","author":"L Zimmer","year":"2017","unstructured":"Zimmer L, Apuri S, Eroglu Z, Kottschade LA, Forschner A, Gutzmer R, et al. Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma. Eur J Cancer. 2017;75:47\u201355. https:\/\/doi.org\/10.1016\/j.ejca.2017.01.009.","journal-title":"Eur J Cancer"},{"issue":"3","key":"509_CR47","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.cell.2018.03.026","volume":"173","author":"SA Shukla","year":"2018","unstructured":"Shukla SA, Bachireddy P, Schilling B, Galonska C, Zhan Q, Bango C, et al. Cancer-germline antigen expression discriminates Clinical outcome to CTLA-4 blockade. Cell. 2018;173(3):624\u201333. https:\/\/doi.org\/10.1016\/j.cell.2018.03.026(e8).","journal-title":"Cell."},{"issue":"6","key":"509_CR48","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1002\/cncr.31889","volume":"125","author":"KR Saab","year":"2019","unstructured":"Saab KR, Mooradian MJ, Wang DY, Chon J, Xia CY, Bialczak A, et al. Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who previously have received programmed cell death protein 1-based therapy. Cancer. 2019;125(6):884\u201391. https:\/\/doi.org\/10.1002\/cncr.31889.","journal-title":"Cancer"},{"issue":"11","key":"509_CR49","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1038\/bjc.2016.321","volume":"115","author":"MS Carlino","year":"2016","unstructured":"Carlino MS, Vanella V, Girgis C, Giannarelli D, Guminski A, Festino L, et al. Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series. Br J Cancer. 2016;115(11):1280\u20134. https:\/\/doi.org\/10.1038\/bjc.2016.321.","journal-title":"Br J Cancer"},{"issue":"17","key":"509_CR50","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1200\/JCO.2017.75.6270","volume":"36","author":"C Robert","year":"2018","unstructured":"Robert C, Ribas A, Hamid O, Daud A, Wolchok JD, Joshua AM, et al. Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma. J Clin Oncol. 2018;36(17):1668\u2013744. https:\/\/doi.org\/10.1200\/JCO.2017.75.6270.","journal-title":"J Clin Oncol"},{"issue":"35","key":"509_CR51","doi-asserted-by":"publisher","first-page":"JCO1801219","DOI":"10.1200\/JCO.18.01219","volume":"36","author":"A Hauschild","year":"2018","unstructured":"Hauschild A, Dummer R, Schadendorf D, Santinami M, Atkinson V, Mandala M, et al. Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAF V600-mutant stage III melanoma. J Clin Oncol. 2018;36(35):JCO1801219. https:\/\/doi.org\/10.1200\/JCO.18.01219.","journal-title":"J Clin Oncol."},{"issue":"7","key":"509_CR52","doi-asserted-by":"publisher","first-page":"617","DOI":"10.2217\/imt-2018-0208","volume":"11","author":"MB Atkins","year":"2019","unstructured":"Atkins MB, Tarhini A, Rael M, Gupte-Singh K, O'Brien E, Ritchings C, et al. Comparative efficacy of combination immunotherapy and targeted therapy in the treatment of BRAF-mutant advanced melanoma: a matching-adjusted indirect comparison. Immunotherapy. 2019;11(7):617\u201329. https:\/\/doi.org\/10.2217\/imt-2018-0208.","journal-title":"Immunotherapy"},{"issue":"5","key":"509_CR53","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s00262-019-02311-1","volume":"68","author":"B Schilling","year":"2019","unstructured":"Schilling B, Martens A, Geukes Foppen MH, Gebhardt C, Hassel JC, Rozeman EA, et al. First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis. Cancer Immunol Immunother. 2019;68(5):765\u201372. https:\/\/doi.org\/10.1007\/s00262-019-02311-1.","journal-title":"Cancer Immunol Immunother"},{"issue":"18","key":"509_CR54","doi-asserted-by":"publisher","first-page":"7637","DOI":"10.1002\/cam4.2625","volume":"8","author":"JC Moser","year":"2019","unstructured":"Moser JC, Chen D, Hu-Lieskovan S, Grossmann KF, Patel S, Colonna SV, et al. Real-world survival of patients with advanced BRAF V600 mutated melanoma treated with front-line BRAF\/MEK inhibitors, anti-PD-1 antibodies, or nivolumab\/ipilimumab. Cancer Med. 2019;8(18):7637\u201343. https:\/\/doi.org\/10.1002\/cam4.2625.","journal-title":"Cancer Med"},{"issue":"14","key":"509_CR55","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","volume":"377","author":"JD Wolchok","year":"2017","unstructured":"Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017;377(14):1345\u201356. https:\/\/doi.org\/10.1056\/NEJMoa1709684.","journal-title":"N Engl J Med"},{"issue":"9992","key":"509_CR56","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","volume":"386","author":"GV Long","year":"2015","unstructured":"Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015;386(9992):444\u201351. https:\/\/doi.org\/10.1016\/S0140-6736(15)60898-4.","journal-title":"Lancet"},{"issue":"6","key":"509_CR57","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1111\/pcmr.12647","volume":"30","author":"KA Malkhasyan","year":"2017","unstructured":"Malkhasyan KA, Zakharia Y, Milhem M. Quality-of-life outcomes in patients with advanced melanoma: a review of the literature. Pigment Cell Melanoma Res. 2017;30(6):511\u201320. https:\/\/doi.org\/10.1111\/pcmr.12647.","journal-title":"Pigment Cell Melanoma Res"},{"issue":"1","key":"509_CR58","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1504030.","journal-title":"N Engl J Med"},{"issue":"2","key":"509_CR59","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1001\/jamaoncol.2018.4514","volume":"5","author":"PA Ascierto","year":"2019","unstructured":"Ascierto PA, Long GV, Robert C, Brady B, Dutriaux C, Di Giacomo AM, et al. Survival outcomes in patients with previously untreated BRAF wild-type advanced melanoma treated with nivolumab therapy: three-year follow-up of a randomized phase 3 trial. JAMA Oncol. 2019;5(2):187\u201394. https:\/\/doi.org\/10.1001\/jamaoncol.2018.4514.","journal-title":"JAMA Oncol"},{"key":"509_CR60","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.ejca.2018.06.034","volume":"101","author":"MS Carlino","year":"2018","unstructured":"Carlino MS, Long GV, Schadendorf D, Robert C, Ribas A, Richtig E, et al. Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: a randomised clinical trial. Eur J Cancer. 2018;101:236\u201343. https:\/\/doi.org\/10.1016\/j.ejca.2018.06.034.","journal-title":"Eur J Cancer"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-020-00509-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40257-020-00509-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-020-00509-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T20:20:43Z","timestamp":1614630043000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40257-020-00509-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,2]]},"references-count":60,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["509"],"URL":"https:\/\/doi.org\/10.1007\/s40257-020-00509-z","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,2]]},"assertion":[{"value":"2 March 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No funding was received to assist in the preparation of this review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Patrick Schummer has received honoraria from Bristol-Myers Squibb (BMS), an institutional research grant from Novartis, and reports travel support from Novartis, Lilly and BMS outside the submitted work. Bastian Schilling reports grants and personal fees from BMS, MSD Sharp & Dohme and Pierre Fabre Pharmaceuticals, and personal fees from Incyte, Novartis, Roche, Pfizer and AMGEN outside the submitted work. Anja Gesierich reports advisory roles for BMS, MSD Sharp & Dohme, Novartis, Roche, Pierre Fabre Pharmaceuticals, Pfizer and Sanofi Genzyme, has received honoraria from MSD Sharp & Dohme, BMS and Roche, and travel support from BMS, MSD Sharp & Dohme, Novartis, Roche and Pierre Fabre Pharmaceuticals outside of the submitted work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}